Mechanism of action
We named this "autologous tumor cell vector" SynVC.
ShinBec is a regenerative medicine product that induces cell death in tumor cells after encapsulating an NKT cell activating compound in the cancer patient's own tumor cells.
The NKT cell activating compound alpha-galactosylceramide (KRN7000) used in Shin-Bec's processing is not a reagent grade manufactured in compliance with GMP standards, but is a clinical trial grade that is actually used in human clinical trials, so a high level of safety is guaranteed.
When Shin Beck is put back into the body of a cancer patient,
1) KRN7000 and tumor antigens (neoantigens) are released from Shin-Beck
2) Both dendritic cells (DCs) and natural killer T (NKT) cells in the body are activated
3) DCs present neoantigens on their cell surface to induce antibody production from tumor-specific killer T cells and B cells.
The above series of reactions attacks the tumor. Ultimately, tumor-specific lymphocytes are retained in the body for a long period of time as memory cells, which is expected to prevent recurrence.
In addition, as long as the cancer patient's own tumor cells can be collected, treatment using ShinBec is not limited to the type of cancer, so it can be used for all cancer treatments.
Treatment process
The procedure for creating Shin Beck is to remove cancer cells from a cancer patient and culture them outside the body for a short period of time (usually 48-72 hours) in order to incorporate NKT cell-activating compounds into the cancer cells. The cultured cells are then collected, and the cancer cells are irradiated with radiation to stop their growth and inactivate them. Shin-Vec can be administered to patients on the same day, but it can also be frozen and stored for long periods of time, so it can be administered on a day that is convenient for the patient.